Ranbaxy Comments on Merck KGaA Generics Rumors, Confirms Federal Raid in NJ - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ranbaxy Comments on Merck KGaA Generics Rumors, Confirms Federal Raid in NJ


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Princeton, NJ (Feb. 15, 2007)—Ranbaxy Inc., part of Ranbaxy Laboratories Ltd. (Gurgaon, India, www.ranbaxy.com) confirmed that federal officials—reportedly including representatives of the US Food and Drug Administration—conducted a search of its New Jersey offices on Feb. 14, 2007.

The company issued the following statement: “Ranbaxy said that this action has come as a surprise. The company is not aware of any wrongdoing. It is cooperating fully with the officials.”

Ranbaxy says its operations are continuing as normal.

Not selling stock
Also, Ranbaxy issued a prepared statement this week to respond to press reports in the Economic Times and Financial Express, which had reported on possible financing vehicles to fund a possible purchase of the generics business of Merck KGaA (Darmstadt, Germany, www.merck.de).

Ranbaxy referenced a Feb. 21, 2007 story in the Economic Times that suggested that promoters of Ranbaxy Laboratories Ltd., the Malvinder and Shivinder Singh families, may sell a small portion of their equity to private equity firms in order to raise money for the possible purchase of Merck’s generics business.

“This is completely untrue and misleading,” said Ranbaxy in prepared statement. “The promoters strongly deny any plan or move on their part to sell any portion of their equity stakes in Ranbaxy to any private equity firm or to any others.”

In response to a Feb. 21 report in the Financial Express that it planned to issue American Depository Shares to buy Merck’s generics business, Ranbaxy said it has no plans to issue any such shares.

ADVERTISEMENT

RELATED CONTENT
Pfizer Plans Additional Cost Cutting
AnorMED accepts Genzyme's Offer of US $13.50 a Share
Merck KGaA to Acquire Majority Stake in Serono for $13.3 Billion
PhRMA Names New Chairman
Chemir Launches IQsynthesis
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
15%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here